Crossbow Therapeutics
Last verified 2026-05-19. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $198.0Mattributed |
|---|---|
| Latest round | series-b, $77.0M, 2026-03-01attributed |
| Founded | 2021 |
| Headquarters | Cambridge, USA |
| Industry | bio |
| Stage | series-b+ |
| Website | crossbowtx.com |
Crossbow Therapeutics develops TCR-mimetic antibody therapies, its T-Bolt molecules, letting off-the-shelf T-cell engagers reach intracellular cancer proteins. It serves biopharma and patients with solid and blood cancers, targeting proteins like TERT. Its edge is opening the full universe of cancer proteins as drug targets.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2026-03-01 | series-b | $77.0M | undisclosed |
Detected tech stack
Google Cloud CDN, Sentry, Partytown, Vercel Speed Insights, WebsiteBuilder, Wix, Google Cloud, React, lodash .
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series B, $77.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $198.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | crossbowtx.com, read 2026-05-19 |
| Description | self-reported | crossbowtx.com, read 2026-05-19 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.